EYLEA Market Sales

Key Factors Driving EYLEA Growth

1. Established Blockbuster Base with Large Patient Pool

• Indications:
  • Wet age-related macular degeneration (wAMD)
  • Diabetic macular edema (DME)
  • Retinal vein occlusion (RVO)
• US sales:
  • ~$4.77B in 2024
• Total US franchise (EYLEA + HD):
  • $5.97B in 2024

Implication:

• • One of the largest ophthalmology markets globally
  • Strong installed base of chronic patients requiring long-term therapy

2. Transition to EYLEA HD (Primary Growth Engine)

• High-dose (8 mg) version approved in 2023
• 2024 U.S. sales:
  • ~$1.2B contribution
• Growth trend:
  • +29% YoY in Q2 2025
  • +54% YoY in early 2025 data

Key advantage:

• Extended dosing intervals (up to every 3–4 months)
• Reduced injection burden vs standard anti-VEGF therapy

3. Lifecycle Management & Label Expansion

• Ongoing regulatory strategies:
  • Expansion into retinal vein occlusion (RVO)
  • Flexible dosing regimens (monthly → extended intervals)
• Potential for:
  • Broader indications
  • Increased dosing flexibility

 

4. Strong Clinical Profile and Physician Trust

• Mechanism:
  • VEGF inhibition → reduces abnormal blood vessel growth
• Long-standing real-world evidence:
  • Proven efficacy in preserving vision
• Impact:
  • High physician confidence
  • Continued use as a standard-of-care therapy globally

 

5. Global Market Expansion (via Bayer ex-US)

• EYLEA marketed globally (Regeneron + Bayer partnership)
• Continued growth outside U.S. via:
  • Emerging markets
  • Aging population

 

6. Growing Disease Burden (Macro Tailwind)

• Drivers:
  • Aging population
  • Rising diabetes prevalence
• Retinal diseases (AMD, DME):
  • Increasing globally

Implication:

• Expanding addressable patient population
• Sustained long-term demand for anti-VEGF therapies

 

EYLEA Recent Developments

• In February 2026, Regeneron Pharmaceuticals announced upcoming presentations from its ophthalmology portfolio and pipeline at the virtual Angiogenesis (Angiogenesis, Exudation, and Degeneration) annual meeting on February 2026. These include new clinical data supporting the efficacy and safety of EYLEA HD (aflibercept) Injection 8 mg for treating patients with serious retinal diseases.

 

“EYLEA Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of EYLEA for approved indication like Branch retinal vein occlusion, Central retinal vein occlusion, Choroidal neovascularisation, Colorectal cancer, Diabetic macular oedema, Diabetic retinopathy, and Glaucoma; as well as potential indication like Polypoidal choroidal vasculopathy in the 7MM. A detailed picture of EYLEA’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the EYLEA for approved and potential indications. The EYLEA market report provides insights about EYLEA’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current EYLEA performance, future market assessments inclusive of the EYLEA market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of EYLEA sales forecasts, along with factors driving its market.

 

EYLEA Drug Summary

EYLEA (Aflibercept) is an FDA-approved recombinant fusion protein developed by Regeneron Pharmaceuticals and Bayer, acting as a decoy receptor that binds and neutralizes vascular endothelial growth factor A (VEGF-A) and placental growth factor (PlGF) to inhibit angiogenesis and vascular leakage in the eye. Administered as an intravitreal injection (2 mg dose in 0.05 mL), it is indicated for neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR), macular edema following retinal vein occlusion (RVO), myopic choroidal neovascularization, and retinopathy of prematurity (ROP), with dosing regimens like every 4-8 or 12 weeks after loading based on disease and response. Pivotal trials (e.g., VIEW, VIVID/VISTA) demonstrated superior or noninferior vision gains versus ranibizumab, with common side effects including conjunctival hemorrhage, eye pain, and increased intraocular pressure, but risks of endophthalmitis, retinal detachment, and vascular events necessitate careful monitoring. High-dose variants like EYLEA HD (8 mg) extend dosing intervals up to 16-24 weeks for nAMD and DME. The report provides EYLEA’s sales, growth barriers and drivers, post usage and approvals in multiple indications. 

 

Scope of the EYLEA Market Report

The report provides insights into:

• A comprehensive product overview including the EYLEA MoA, description, dosage and administration, research and development activities in approved indications like Branch retinal vein occlusion, Central retinal vein occlusion, Choroidal neovascularisation, Colorectal cancer, Diabetic macular oedema, Diabetic retinopathy, and Glaucoma; as well as potential indication like Polypoidal choroidal vasculopathy.
• Elaborated details on EYLEA regulatory milestones and other development activities have been provided in EYLEA market report.
• The report also highlights EYLEA‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The EYLEA market report also covers the patents information, generic entry and impact on cost cut.
• The EYLEA market report contains current and forecasted EYLEA sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The EYLEA market report also features the SWOT analysis with analyst views for EYLEA in approved and potential indications.

 

Methodology

The EYLEA market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

 

EYLEA Analytical Perspective by DelveInsight

In-depth EYLEA Market Assessment

This EYLEA sales market forecast report provides a detailed market assessment of EYLEA for approved indication like Branch retinal vein occlusion, Central retinal vein occlusion, Choroidal neovascularisation, Colorectal cancer, Diabetic macular oedema, Diabetic retinopathy, and Glaucoma; as well as potential indication like Polypoidal choroidal vasculopathy in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted EYLEA sales data uptil 2034.

 

EYLEA Clinical Assessment

The EYLEA market report provides the clinical trials information of EYLEA for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

EYLEA Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

 

EYLEA Market Potential & Revenue Forecast

• Projected market size for the EYLEA and its key indications
• Estimated EYLEA sales potential (EYLEA peak sales forecasts)
• EYLEA Pricing strategies and reimbursement landscape

 

EYLEA Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• EYLEA Market positioning compared to existing treatments
• EYLEA Strengths & weaknesses relative to competitors

 

EYLEA Regulatory & Commercial Milestones

• EYLEA Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

 

EYLEA Clinical Differentiation

• EYLEA Efficacy & safety advantages over existing drugs
• EYLEA Unique selling points  

 

EYLEA Market Report Highlights

• In the coming years, the EYLEA market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The EYLEA companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence EYLEA’s dominance.
• Other emerging products for Branch retinal vein occlusion, Central retinal vein occlusion, Choroidal neovascularisation, Colorectal cancer, Diabetic macular oedema, Diabetic retinopathy, and Glaucoma; as well as potential indication like Polypoidal choroidal vasculopathy are expected to give tough market competition to EYLEA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of EYLEA in approved and potential indications.
• Analyse EYLEA cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted EYLEA sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of EYLEA in approved and potential indications.

 

Key Questions Answered In The EYLEA Market Report

• What is the class of therapy, route of administration and mechanism of action of EYLEA? How strong is EYLEA’s clinical and commercial performance?
• What is EYLEA’s clinical trial status in each individual indications such as Branch retinal vein occlusion, Central retinal vein occlusion, Choroidal neovascularisation, Colorectal cancer, Diabetic macular oedema, Diabetic retinopathy, and Glaucoma; as well as potential indication like Polypoidal choroidal vasculopathy and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the EYLEA Manufacturers?
• What are the key designations that have been granted to EYLEA for approved and potential indications? How are they going to impact EYLEA’s penetration in various geographies?
• What is the current and forecasted EYLEA market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of EYLEA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan? 
• What are the other emerging products available and how are these giving competition to EYLEA for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is EYLEA? What is the duration of therapy and what are the geographical variations in cost per patient?